Evidence map›Paper›PMID 27579733›Full record

ArticleThe British journal of dermatology2017

Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study.

D A Springate, R Parisi, E Kontopantelis, D Reeves, C E M Griffiths, D M Ashcroft

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 14 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 14 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

D A SpringateNIHR School for Primary Care Research (Centre for Primary Care), University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, U.K.
R ParisiCentre for Pharmacoepidemiology and Drug Safety, Manchester Pharmacy School, University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, U.K.
E KontopantelisNIHR School for Primary Care Research (Centre for Primary Care), University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, U.K.
D ReevesNIHR School for Primary Care Research (Centre for Primary Care), University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, U.K.
C E M GriffithsDermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K.
D M AshcroftNIHR School for Primary Care Research (Centre for Primary Care), University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, U.K.

Funding

Medical Research Council MR/K006665/1
6 · The paper itself

Abstract

backgroundThe burden of psoriasis across many world regions is high and there is a recognized need to better understand the epidemiology of this common skin disorder.

objectivesTo examine changes in the prevalence and incidence of psoriasis, and mortality rates over a 15-year period.

methodsCohort study involving analysis of longitudinal electronic health records between 1999 and 2013 using the U.K. Clinical Practice Research Datalink (CPRD).

resultsThe prevalence of psoriasis increased steadily from 2·3% (2297 cases per 100 000) in 1999 to 2·8% (2815 per 100 000) in 2013, which does not appear to be attributable to changes in incidence rates. We observed peaks in age bands characteristic of early-onset (type I) and late-onset (type II) psoriasis, and changes in incidence and prevalence rates with increasing latitude in the U.K. All-cause mortality rates for the general population and for patients with psoriasis have decreased over the last 15 years. However, the risk of all-cause mortality for patients with psoriasis remains elevated compared with people without psoriasis (hazard ratio 1·21; 95% confidence interval 1·13-1·3) and we found no significant change in this relative excess mortality gap over time.

conclusionsWe found an increasing population living longer with psoriasis in the U.K., which has important implications for healthcare service delivery and for resource allocation. Importantly, early mortality in patients with psoriasis remains elevated compared with the general population and we found no evidence of change in this premature mortality gap.

Indexed as

AdolescentAdultAgedAged, 80 and overAge DistributionChildChild, PreschoolEpidemiologic MethodsFemaleHumansInfantInfant, NewbornMaleMiddle AgedMortalityPsoriasis

Identifiers

PMID27579733
PMCPMC5363241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.